ND0612

NeuroDerm is developing ND0612 for the treatment of moderate to severe stage Parkinson’s disease patients for whom oral drugs are no longer effective enough. ND0612 has been designed to be a safer, more effective and convenient alternative to current treatment modalities that involve surgery, such as deep brain stimulation (DBS) and levodopa/carbidopa intestinal gel (LCIG, Duodopa in Europe and Duopa in the United States).

twopumps

ND0612 belt pump

A simple, daily, convenient drug pump that delivers LD/CD to treat severe Parkinson’s disease patients.

ND0612 has been designed to provide continuous subcutaneous delivery of an adjustable, LD/CD formulation to significantly improve motor and non-motor complications in patients treated with oral LD/CD.
ND0612 subcutaneous administration – utilizing a convenient belt-pump (resembling the administration of insulin to diabetic patients) – allows patients to receive continuous LD/CD therapy on a 24 hour basis, thus improving morning “off” time and ensuring a good night’s sleep.
NeuroDerm believes that ND0612 will be a first-line treatment alternative for Parkinson’s patients experiencing motor fluctuations, preceding and replacing the surgical treatment alternatives currently offered to severe stage patients.

NeuroDerm completed a Phase II program with ND0612. In these studies, plasma levodopa concentrations achieved in Parkinson’s disease patients, as well as efficacy measurements demonstrated with ND0612 indicate that ND0612 may offer a viable alternative to more invasive surgical procedures for advanced Parkinson’s Disease.